Corcept Therapeutics Incorporated

Healthcare · Biotechnology

118.50$ +4.9% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Income Statement

Corcept Therapeutics Incorporated (CORT) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 256 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement CORT
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	22	24	28	36	43	53	58	62	64	67	65	72	82	88	93	89	86	86	79	92	96	99	94	103	102	103	106	118	124	135	147	164	183	182	157	194	208	202	165	256	831
Cost of Revenue	0.7	0.6	0.6	0.8	1.0	1.2	1.2	1.2	1.3	1.6	1.2	1.4	1.5	1.4	1.9	1.2	1.2	1.3	1.3	1.4	1.3	1.4	1.3	1.3	1.3	1.5	1.4	1.6	1.6	1.9	2.5	2.5	2.9	3.0	2.4	3.4	4.6	2.5	2.9	4.1	14
Gross Profit	21	23	27	35	42	52	56	61	63	65	64	71	80	86	91	87	85	84	78	90	95	97	92	102	100	102	104	116	122	134	144	161	180	179	155	191	203	200	162	252	817
Research & Development	7.1	6.5	7.2	7.9	12	14	17	21	19	19	20	22	23	24	26	26	34	28	29	28	28	29	28	33	33	37	41	43	46	55	59	59	59	70	61	60	69	65	66	54	254
Selling, General & Administrative	11	12	15	14	16	17	18	20	21	22	24	25	24	27	28	26	27	105	30	30	31	32	38	38	35	42	49	43	45	47	56	67	74	83	91	104	124	130	145	157	556
Total Operating Expenses	18	18	22	22	28	30	35	41	40	40	45	46	47	51	54	52	60	54	59	58	59	61	66	71	68	79	89	87	91	102	115	126	133	154	151	164	193	195	212	211	810
Operating Income	3.1	5.0	4.7	13	14	22	21	21	23	25	19	25	33	35	38	35	25	31	20	32	36	37	27	31	32	22	15	30	31	32	30	36	47	25	3.4	27	10	4.5	-50	41	6.4
Interest Expense	0.5	0.4	0.2	0.1	0.1	0.2	0.3	0.6	0.8	1.0	1.1	1.2	1.3	1.4	1.5	1.0	0.6	0.3	0.3	0.1	0.1	0.1	0.1	0.6	1.1	1.8	3.6	–	–	3.6	–	–	–	–	–	–	–	–	–	–	–
Pre-Tax Income	2.6	4.6	4.5	13	14	22	21	21	24	26	20	26	34	36	39	36	25	31	20	32	36	37	27	32	33	24	18	33	36	37	35	42	53	32	9.6	32	15	9.9	-45	46	26
Income Tax Expense	0.0	0.0	0.1	0.1	0.0	-76	3.8	3.0	6.0	3.9	1.8	5.6	8.0	7.1	9.1	7.9	3.7	4.8	-3.6	5.5	5.8	4.7	4.1	4.7	-1.6	7.7	2.6	5.4	5.0	5.5	7.2	6.1	5.7	1.2	-11	-3.5	-4.4	-14	-14	-2.9	-35
Net Income	2.6	4.6	4.4	13	14	98	17	18	18	22	18	20	26	29	30	28	22	26	23	27	30	32	23	27	35	17	16	28	31	31	28	35	47	30	21	35	20	24	-31	42	55
EBITDA	3.1	5.0	4.8	13	14	22	21	21	23	25	19	25	34	36	38	36	25	31	20	33	37	38	28	33	34	25	19	33	37	37	35	42	53	32	10	32	16	10	-44	47	29

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings